

Assessment of Histopathological Changes in Gastric Biopsy Specimen Associated with *Helicobacter pylori* Infection and Intestinal Metaplasia

Arawinth Karthic^{1*}, Dr. Sridevi², Saranya Varadarajan³, Dr. Samya Varadarajan⁴ and Thodur Madapusi Balaji⁵

¹Saveetha Medical College, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai- India

²Saveetha Medical College, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai- India

³Department of Oral Pathology and Microbiology, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University Chennai - 600 077, India

⁴Associate Professor, Department of Community Medicine, Sri Ramachandra Medical College, Sri Ramachandra Institute of Higher Education and Research, Porur, Chennai

⁵MDS PhD, Tagore Dental College and Hospital, Near Vandalur, Melakkottaiyur Post, Rathinamangalam, Tamil Nadu 600127, India

Email id: ³vsaranya87@gmail.com and ⁴samya.v@sriramachandra.edu.in

Orcid id: ⁴0000-0002-6396-5593

Received: 28th Feb, 2026; Revised: 6th March 2026; Accepted: 7th April, 2026; Available Online: 20th April, 2026

ABSTRACT

It is a well-known fact that *Helicobacter pylori* (*H. pylori*), a gram-negative bacterium, causes chronic gastritis and peptic ulcers which in turn aids in gastric carcinogenesis. *H. pylori* induces chronic inflammation of the gastric mucosa which leads to a precancerous state known as intestinal metaplasia (IM). With the available information we conducted the present study to elucidate the extent of *Helicobacter pylori* (*H. pylori*) infection and the histopathological characteristics of intestinal metaplasia in gastric biopsy specimens, stratified by gender and age. This retrospective cross-sectional observational study was conducted in Saveetha Medical College, Chennai, India using gastric biopsy specimens collected from March 2023 to January 2024. Hematoxylin and Eosin and Giemsa stains were done on the study samples and analysed. Specimens were assessed for inflammation, atrophy, and intestinal metaplasia. Data were subjected to statistical analysis using Chi Square test. In the present study 68.3% were males. *H. pylori* positivity was found in 55% of patients and presence of *H. pylori* was greater in males (63.6%). Intestinal metaplasia was identified in 16.7% of patients, 90% were males. *H. pylori* infection was greater in age group between 21 and 40 while intestinal metaplasia was most frequent in individuals between 41-50 years. Thus, early diagnosis of *H. pylori* and Intestinal metaplasia could aid in prevention of gastric carcinogenesis and improve prognosis of patients

Keywords: *Helicobacter pylori*, gastric biopsy, intestinal metaplasia, histopathology,

How to cite this article: Karthic A, Sridevi, Varadarajan S, Varadarajan S, Balaji TM, Assessment of Histopathological Changes in Gastric Biopsy Specimen Associated with *Helicobacter pylori* Infection and Intestinal Metaplasia. Int J Drug Deliv Technol. 2026;16(6): 517-521. DOI: 10.25258/ijddt.16.6.59

Source of support: Nil.

Conflict of interest: None

INTRODUCTION

Helicobacter pylori (*H. pylori*), a gram-negative bacterium the primary cause of chronic gastritis and peptic ulcers and is also known to be associated with gastric carcinogenesis.

¹. Intestinal metaplasia (IM) is nothing but a precancerous transformation of gastric mucosa, commonly driven by persistent *H. pylori*-induced inflammation ². The term metaplasia refers to the change of one particular differentiated cell type to another ³Therefore, intestinal metaplasia refers to a condition in which gastric mucosa is replaced by intestinal mucosa. Of the two histopathological subtypes, the complete and incomplete ones, the incomplete one has a greater malignant transformation rate ⁴

Early diagnosis of gastric ulcer, intestinal metaplasia, and *H. pylori* infection is essential to improve the prognosis of the disease and prevent malignant transformation.

The different methods of detecting *H. pylori* infection include detection of faecal *H. pylori* antigen, carbon-13 urea breath testing, rapid urease analysis, serological detection, microbial culture, endoscopy, Polymerase Chain reaction (PCR), fluorescent quantitative PCR, and various methods adopting in-situ hybridization technology ⁵⁻⁷ Each of these methods has relative advantages and disadvantages. However, currently, histopathology is considered the Gold Standard for the detection of *H. pylori* and Intestinal metaplasia. The histopathologic features of chronic *H. pylori* infection with intestinal metaplasia

*Author for Correspondence: Arawinth Karthic

include glandular atrophy that is characterized by atrophic changes of the gastric glands, replacement of gastric mucosa by fibrous tissue, and replacement of gastric mucosa by intestinal mucosa. These are the key features of intestinal metaplasia include glandular atrophy, goblet cell hyperplasia, and MUC 2 expression⁸⁻¹⁰.

Also, with the recent development of endoscopic examination, endoscopic biopsy, and histopathological diagnosis have gained importance¹¹⁻¹³. The World Health Organization recently clarified *H. pylori* as a carcinogen of gastric cancer^{14,15}. In this regard, several authors have assessed the presence of *H. pylori* in the gastric mucosa via histopathology and the associated findings, such as gastritis, metaplasia, and atrophy in several geographic areas and confirmed that *Helicobacter pylori* infection is the most important risk factor for gastric cancer, and management of *H. Pylori* infection will definitely reduce the risk of malignant transformation of the gastric mucosa¹⁵⁻²⁰.

Histopathological analysis not only aids in early diagnosis but could also serve as a prognostic marker and aid in the treatment of the condition, and prevent malignant transformation. Although several studies have reported the association of *H. Pylori* and intestinal metaplasia, very few studies have determined the age and gender prevalence of *H. Pylori*.

With the available information, the present retrospective study was conducted to elucidate age and gender variations of *Helicobacter pylori* infection and the histopathological characteristics of intestinal metaplasia in gastric biopsy specimens of the stomach.

METHODS

Ethical Approval: Institutional ethical clearance was obtained prior to study initiation

Study Design and Setting: This retrospective cross-sectional study was conducted in the Department of Pathology at Saveetha Medical College between March 2023 and January 2024.

Participants: Gastric biopsy specimens (n=60) from patients with confirmed *H. pylori* infection were analyzed. Inclusion criteria: adults >18 years, gastric biopsies from the antrum/pylorus, histologically diagnosed *H. pylori* infection. Exclusion: history of prior *H. pylori* eradication therapy or incomplete records. Biopsies were selected using convenience sampling from the archives of the pathology department based on the availability of confirmed *H. pylori* diagnosis and complete demographic data. Due to the retrospective nature of the study, patient consent was waived, as approved by the Institutional Ethics Committee.

Data Sources and Measurement: Biopsy specimens were fixed in 10% buffered formalin, dehydrated, embedded in paraffin, and sectioned at 4 microns. Slides were stained using Hematoxylin & Eosin (H&E) for general morphology and Giemsa stain for *H. pylori* detection. The

prepared sections after staining were examined under the light microscope for histopathological changes such as inflammation, atrophy, and intestinal metaplasia.

Variables:

- **Primary Outcome:** Presence and severity of *H. pylori* infection
- **Secondary Outcome:** Presence of intestinal metaplasia
- **Exposures:** Age group, gender

Statistical Analysis: Data were analyzed using Microsoft Excel. Descriptive statistics were computed. Group comparisons were performed using chi-square tests. Significance threshold was set at $p < 0.05$.

RESULTS

Of the 60 participants, 41 were males, constituting 68.3% and 19 were females (31.7%). 35 patients (58.3%) were below 40 years of age; 25 (41.7%) were above 40 years of age. 33 (55%) were positive for *H. Pylori* infection, and 27 were negative. Among *H. pylori*-positive cases, 21 were males. 16 patients had mild activity, and 17 demonstrated moderate activity. High activity of *H. Pylori* was found in 9 males (56.2%) and 7 females. Moderate activity was present in 12 males and 5 females.

Considering the age group, *H. Pylori* was positive in 9 patients of age between 21 and 30 and 12 patients of age between 31 and 40, whereas only 2 patients of age groups 10-20 and 71-80 years showed *H. Pylori* positivity.

Considering Intestinal metaplasia, 10 patients of 60 who were screened had metaplasia, of which 9 were males, and only 1 was female. Most of the patients with Intestinal metaplasia were aged between 41 and 50 years of age.

Statistical analysis

Gender variation with *H. pylori* infection was statistically significant ($p < 0.05$). A statistically significant difference was observed in the distribution of *H. pylori* severity between genders ($p = 0.042$). While moderate activity was more common in males, females more frequently had mild activity. Age and gender variations of Intestinal metaplasia were statistically significant ($p < 0.05$). The results are depicted in tables 1,2,3, and 4.

Inference of the study

H. Pylori infection with Intestinal metaplasia was more common in males and patients between 40 to 50 years of age.

DISCUSSION

With the increasing prevalence of gastric carcinoma associated with high morbidity and mortality rates, early diagnosis and prompt treatment have become the need of the hour. Considering the etiology of the condition, gastric ulcers caused by *H. Pylori* infection have been attributed to cause a lot of changes in the gastric mucosa, leading to intestinal metaplasia. *H. pylori* infection has increased over recent years, with about 4.4 billion individuals affected

globally ²¹Intestinal metaplasia is a pre-cancerous condition with a high malignant transformation rate, which could be aggravated by chronic inflammation associated with gastritis and peptic ulcer. Although there are several diagnostic methods to detect *H. Pylori* and intestinal metaplasia, endoscopic biopsy and histopathological examination remain the gold standard. Very few studies have reported the age and gender predilection of *H. Pylori* and intestinal metaplasia. With the available information, the present study was conducted to elucidate the extent of *Helicobacter pylori* (*H. pylori*) infection and the histopathological characteristics of intestinal metaplasia in gastric biopsy specimens, stratified by gender and age²²

Our study results have shown that 55% of the population were positive for *H. Pylori*. Several authors have reported increased prevalence of *H. Pylori* in underdeveloped and developing countries in comparison with developed countries ²¹In the present study, *H. Pylori* infection was more predominant in males, which was statistically significant. The findings are concurrent with those of Wu et al 2022 who reported a greater percentage of *H. Pylori* in males and attributed it to factors such as diabetes, hypertension, low albumin, high BMI, and older age. Hormonal factors such as oestrogen could also play a role in immunity and inflammation, leading to a male predominance ^{23,24}. This male predominance could also be attributed to the associated habit-related factors, such as smoking and alcoholism.

Considering age, a few epidemiological studies have attributed differences in prevalence associated with age ²⁵. In the present study, *H. Pylori* was more prevalent in patients aged between 31-40 years, which was not significant, which could be due to the low sample size. This could be attributed to the fact that the host's immune response could alter the microbial colonization²⁶. Studies have reported that the infection is acquired in childhood, and the present results could be attributed to the small sample size ²⁷Considering the activity of *H. Pylori*, 48.5% had mild and 51.5% had moderate activity. Moderate activity is associated with increased inflammation and complications such as peptic ulcer and intestinal metaplasia.

16% of patients had a positivity for Intestinal Metaplasia, and a male predominance was observed and who belonged with 41- 50 years of age, and they were statistically significant. The study results are concurrent with those of Craanen et al, who reported intestinal metaplasia in *H. Pylori* patents greater than 50 years of age ²⁸This could be attributed to factors such as tobacco, alcohol consumption, hormonal changes, and host immune response. ²⁹

The study results shed light on the fact that histopathological evaluation of gastric biopsy samples will aid in early diagnosis and prevention of carcinogenesis. This study is limited by its small sample size and single-center design, which may limit generalizability. Additionally, lifestyle factors such as diet, smoking, and alcohol use—which may affect *H. pylori* infection and

metaplasia—were not recorded. Larger, metacentric prospective studies are needed to better understand the temporal relationship between *H. pylori* infection and progression to intestinal metaplasia across diverse populations.

CONCLUSION

The current research sheds light on the presence of *H. Pylori* infection and intestinal metaplasia in gastric biopsy specimens. *H. Pylori* was predominant in males at a younger age; however, intestinal metaplasia was more predominant in males of the older age group. The exact factors responsible for intestinal metaplasia have to be analyzed for the development of therapeutic strategies and the prevention of carcinogenesis. Histopathological surveillance in high-risk populations may aid in early intervention and potential reversal of precancerous gastric changes.

REFERENCES

1. Narayanan M, Reddy KM, Marsicano E. Peptic Ulcer Disease and *Helicobacter pylori* infection. *Mo Med*. 2018;115(3):219–24. PubMed PMID: 30228726.
2. Correa P, Piazuelo BM, Wilson KT. Pathology of Gastric Intestinal Metaplasia: Clinical Implications. *American Journal of Gastroenterology*. 2010 Mar;105(3):493–8. doi:10.1038/ajg.2009.728
3. Giroux V, Rustgi AK. Metaplasia: tissue injury adaptation and a precursor to the dysplasia–cancer sequence. *Nat Rev Cancer*. 2017 Oct 1;17(10):594–604. doi:10.1038/nrc.2017.68
4. Du S, Yang Y, Fang S, Guo S, Xu C, Zhang P, et al. Gastric Cancer Risk of Intestinal Metaplasia Subtypes: A Systematic Review and Meta-Analysis of Cohort Studies. *Clin Transl Gastroenterol*. 2021 Oct;12(10):e00402. doi:10.14309/ctg.0000000000000402
5. Sabbagh P, Mohammadnia-Afrouzi M, Javanian M, Babazadeh A, Koppolu V, Vasigala VR, et al. Diagnostic methods for *Helicobacter pylori* infection: ideals, options, and limitations. *European Journal of Clinical Microbiology & Infectious Diseases*. 2019 Jan 9;38(1):55–66. doi:10.1007/s10096-018-3414-4
6. Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, et al. Management of *Helicobacter pylori* infection—the Maastricht V/Florence Consensus Report. *Gut*. 2017 Jan;66(1):6–30. doi:10.1136/gutjnl-2016-312288
7. Huh CW, Kim BW. Diagnosis of *Helicobacter pylori* Infection. *The Korean Journal of Gastroenterology*. 2018;72(5):229. doi:10.4166/kjg.2018.72.5.229
8. Gulmann C, Shaqqa O Al, Grace A, Leader M, Patchett S, Butler D, et al. Cytokeratin 7/20 and MUC1, 2, 5AC, and 6 Expression Patterns in Barrett's Esophagus and Intestinal Metaplasia of the Stomach. *Applied Immunohistochemistry & Molecular Morphology*. 2004 Jun;142–7.

doi:10.1097/00129039-200406000-00008

9. Sung JY, Lin S, Ching JYL, Zhou L, To KF, Wang R, et al. Atrophy and intestinal metaplasia one year after cure of *H. pylori* infection: A prospective, randomized study. *Gastroenterology*. 2000 Jul;119(1):7–14. doi:10.1053/gast.2000.8550
10. Barmapoutis P, Waddingham W, Yuan J, Ross C, Kayhanian H, Stathaki T, et al. A digital pathology workflow for the segmentation and classification of gastric glands: Study of gastric atrophy and intestinal metaplasia cases. *PLoS One*. 2022 Dec 30;17(12):e0275232. doi:10.1371/journal.pone.0275232
11. Chatrangsun B, Vilaichone RK. Endoscopic Diagnosis for *H. pylori* Infection: White Light Imaging (WLI) vs. Image-Enhanced Endoscopy (IEE). *Asian Pacific Journal of Cancer Prevention*. 2021 Sep 1;22(9):3031–8. doi:10.31557/APJCP.2021.22.9.3031
12. Watanabe T, Nadatani Y, Suda W, Higashimori A, Otani K, Fukunaga S, et al. Long-term persistence of gastric dysbiosis after eradication of *Helicobacter pylori* in patients who underwent endoscopic submucosal dissection for early gastric cancer. *Gastric Cancer*. 2021 May 17;24(3):710–20. doi:10.1007/s10120-020-01141-w
13. Tiwari A, Rai R, Dahal P, Regmi S. Prevalence of *Helicobacter Pylori* in Endoscopic Gastric Biopsies of Chronic Gastritis Patients at A Tertiary Care Centre. *Journal of Nepal Medical Association*. 2020 Aug 31;58(228). doi:10.31729/jnma.5210
14. Suzuki H, Mori H. World trends for *H. pylori* eradication therapy and gastric cancer prevention strategy by *H. pylori* test-and-treat. *J Gastroenterol*. 2018 Mar 14;53(3):354–61. doi:10.1007/s00535-017-1407-1
15. Khatoon J, Prasad KN, Prakash Rai R, Ghoshal UC, Krishnani N. Association of heterogenicity of *Helicobacter pylori* cag pathogenicity island with peptic ulcer diseases and gastric cancer. *Br J Biomed Sci*. 2017 Jul 3;74(3):121–6. doi:10.1080/09674845.2017.1278887
16. Salar A. Linfoma MALT gástrico y *Helicobacter pylori*. *Med Clin (Barc)*. 2019 Jan;152(2):65–71. doi:10.1016/j.medcli.2018.09.006
17. Marques MS, Melo J, Cavadas B, Mendes N, Pereira L, Carneiro F, et al. Afadin Downregulation by *Helicobacter pylori* Induces Epithelial to Mesenchymal Transition in Gastric Cells. *Front Microbiol*. 2018 Nov 9;9. doi:10.3389/fmicb.2018.02712
18. Quach DT, Vilaichone R korn, Vu K Van, Yamaoka Y, Sugano K, Mahachai V. *Helicobacter pylori* Infection and Related Gastrointestinal Diseases in Southeast Asian Countries: An Expert Opinion Survey. *Asian Pacific Journal of Cancer Prevention*. 2018 Dec 1;19(12):3565–9. doi:10.31557/APJCP.2018.19.12.3565
19. El-Zimaity HMT, Graham DY. Evaluation of gastric mucosal biopsy site and number for identification of *Helicobacter pylori* or intestinal metaplasia: Role of the sydney system. *Hum Pathol*. 1999 Jan;30(1):72–7. doi:10.1016/S0046-8177(99)90303-9
20. Take S, Mizuno M, Ishiki K, Hamada F, Yoshida T, Yokota K, et al. Low Incidence of Esophageal Adenocarcinoma After Eradication of *Helicobacter pylori* in Japan. *Clinical Gastroenterology and Hepatology*. 2018 Dec;16(12):1995–6. doi:10.1016/j.cgh.2018.03.030
21. Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, et al. Global Prevalence of *Helicobacter pylori* Infection: Systematic Review and Meta-Analysis. *Gastroenterology*. 2017 Aug;153(2):420–9. doi:10.1053/j.gastro.2017.04.022
22. Sung JY, Coker OO, Chu E, Szeto CH, Luk STY, Lau HCH, et al. Gastric microbes associated with gastric inflammation, atrophy and intestinal metaplasia 1 year after *Helicobacter pylori* eradication. *Gut*. 2020 Sep;69(9):1572–81. doi:10.1136/gutjnl-2019-319826
23. Wu Y, Zeng H, Zhang M, Li C, Tang Y, Li X, et al. Sex-Specific Risk Factors Associated with *Helicobacter pylori* Infection Among Individuals Undergoing Health Examinations in China. *Int J Gen Med*. 2022 Jun;Volume 15:5861–8. doi:10.2147/IJGM.S367142
24. de Martel C, Parsonnet J. *Helicobacter pylori* Infection and Gender: A Meta-Analysis of Population-Based Prevalence Surveys. *Dig Dis Sci*. 2006 Dec 7;51(12):2292–301. doi:10.1007/s10620-006-9210-5
25. Chen T, Hung H, Chen M, Lai H, Hsu W, Huang K, et al. *Helicobacter Pylori* Infection is Positively Associated with Metabolic Syndrome in Taiwanese Adults: a Cross-Sectional Study. *Helicobacter*. 2015 Jun 12;20(3):184–91. doi:10.1111/hel.12190
26. Araújo GRL, Marques HS, Santos MLC, Silva FAF da, Brito BB de, Santos GLC, et al. *Helicobacter pylori* infection: How does age influence the inflammatory pattern? *World J Gastroenterol*. 2022 Jan 28;28(4):402–11. doi:10.3748/wjg.v28.i4.402
27. Asgeirsdottir GA, Kjartansdottir I, Olafsdottir AS, Hreinsson JP, Hrafnkelsson H, Johannsson E, et al. *Helicobacter pylori* infection in Icelandic children. *Scand J Gastroenterol*. 2017 Jul 3;52(6–7):686–90. doi:10.1080/00365521.2017.1304986
28. Craanen ME, Dekker W, Blok P, Ferwerda J, Tytgat

GN. Intestinal metaplasia and *Helicobacter pylori*: an endoscopic bioptic study of the gastric antrum. Gut. 1992 Jan 1;33(1):16–20. doi:10.1136/gut.33.1.16

Pathogenesis and potential reversibility of intestinal metaplasia – a milestone in gastric carcinogenesis. Radiol Oncol. 2024 Jun 1;58(2):186–95. doi:10.2478/raon-2024-0028

29. Drnovsek J, Homan M, Zidar N, Smid LM.

Table 1: Demographic Characteristics of the Study Population (n=60)

Demographic Characteristic	No of patients	Percentage
Gender		
Male	41	68.3
Female	19	31.7
Age Group		
- 10-20	5	8.3
- 21-30	15	25.0
- 31-40	20	33.3
- 41-50	10	16.7
- 51-60	7	11.7
- 71-80	3	5.0

Table 2: *H. pylori* Infection by Gender and Age Group

Group	<i>H. pylori</i> Positive (n=33)	<i>H. pylori</i> Negative (n=27)
Male	21	18
Female	12	9
21-30 years	9	6
31-40 years	12	8
Other ages	12	13

Table 3: Distribution of Intestinal Metaplasia by Gender and Age

Variable	IM Present (n=10)	IM Absent (n=50)
Male	9	32
Female	1	18
41-50 years	4	6
51-60 years	3	4

Table 4: Severity of *H. pylori* Activity by Gender

Severity of <i>H. pylori</i> Activity	Male (n=21)	Female (n=12)	Total (n=33)	p-value
Mild	7 (33.3%)	9 (75.0%)	16 (48.5%)	
Moderate	12 (57.1%)	5 (41.7%)	17 (51.5%)	
Total	21	12	33	0.042*